NeuroMetrix, Inc. (NURO): Price and Financial Metrics


NeuroMetrix, Inc. (NURO): $4.01

-0.05 (-1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NURO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NURO POWR Grades


  • Sentiment is the dimension where NURO ranks best; there it ranks ahead of 75.61% of US stocks.
  • NURO's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • NURO ranks lowest in Stability; there it ranks in the 6th percentile.

NURO Stock Summary

  • With a market capitalization of $30,276,395, NeuroMetrix Inc has a greater market value than only 5.72% of US stocks.
  • The volatility of NeuroMetrix Inc's share price is greater than that of 97.57% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NURO comes in at -64.58% -- higher than that of only 6.57% of stocks in our set.
  • Stocks that are quantitatively similar to NURO, based on their financial statements, market capitalization, and price volatility, are SCWX, NTGR, RNLX, DIOD, and LKCO.
  • NURO's SEC filings can be seen here. And to visit NeuroMetrix Inc's official web site, go to www.neurometrix.com.

NURO Valuation Summary

  • In comparison to the median Healthcare stock, NURO's price/earnings ratio is 256.71% lower, now standing at -57.2.
  • NURO's price/sales ratio has moved up 0.9 over the prior 208 months.
  • NURO's price/sales ratio has moved up 0.9 over the prior 208 months.

Below are key valuation metrics over time for NURO.

Stock Date P/S P/B P/E EV/EBIT
NURO 2021-08-31 8.2 7.6 -57.2 -50.8
NURO 2021-08-30 9.5 8.8 -66.5 -60.1
NURO 2021-08-27 11.3 10.5 -79.1 -72.7
NURO 2021-08-26 6.8 6.3 -47.8 -41.3
NURO 2021-08-25 7.1 6.6 -49.9 -43.4
NURO 2021-08-24 7.8 7.2 -54.3 -47.8

NURO Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 76.94%.
  • The 3 year net cashflow from operations growth rate now stands at 108.54%.
  • Its 5 year cash and equivalents growth rate is now at -67.77%.
Over the past 15 months, NURO's revenue has gone up $978,347.

The table below shows NURO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 8.253493 -2.073694 -2.281457
2021-09-30 8.243062 -1.280035 -1.604223
2021-06-30 8.214931 -0.803839 -1.174247
2021-03-31 7.361411 -1.337473 -1.494607
2020-12-31 7.377975 -2.066861 -2.092195
2020-09-30 7.275146 -2.409208 -2.823158

NURO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NURO has a Quality Grade of D, ranking ahead of 21.62% of graded US stocks.
  • NURO's asset turnover comes in at 0.625 -- ranking 66th of 186 Medical Equipment stocks.
  • BLFS, NVNO, and ZYXI are the stocks whose asset turnover ratios are most correlated with NURO.

The table below shows NURO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.625 0.729 -0.970
2021-06-30 0.944 0.739 -0.690
2021-03-31 0.902 0.717 -0.828
2020-12-31 0.948 0.712 -1.087
2020-09-30 0.969 0.684 -1.415
2020-06-30 0.970 0.635 -1.936

NURO Stock Price Chart Interactive Chart >

Price chart for NURO

NURO Price/Volume Stats

Current price $4.01 52-week high $38.75
Prev. close $4.06 52-week low $2.70
Day low $3.91 Volume 470,071
Day high $4.22 Avg. volume 1,789,412
50-day MA $3.82 Dividend yield N/A
200-day MA $6.48 Market Cap 28.59M

NeuroMetrix, Inc. (NURO) Company Bio


NeuroMetrix Inc. is a medical device company that designs, develops and sells proprietary products used to diagnose neuropathies. The Company's neuropathy diagnostic system provides primary care and specialist physicians objective information that aids in the diagnosis of neuropathies at the point of service.


NURO Latest News Stream


Event/Time News Detail
Loading, please wait...

NURO Latest Social Stream


Loading social stream, please wait...

View Full NURO Social Stream

Latest NURO News From Around the Web

Below are the latest news stories about NeuroMetrix Inc that investors may wish to consider to help them evaluate NURO as an investment opportunity.

NeuroMetrix''s Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome

NeuroMetrix Inc''s (NASDAQ: NURO ) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Quell is an advanced, non-invasive neuromodulation technology covered by 22 U.S. utility patents and numerous … Full story available on Benzinga.com

Benzinga | February 24, 2022

NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome

NeuroMetrix Inc's (NASDAQ: NURO) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Quell is an advanced, non-invasive neuromodulation technology covered by 22 U.S. utility patents and numerous international patents. It is the only wearable neuromodulator enabled by a proprietary microchip that provides precise, high-power nerve stimulation in a form factor the size of a credit card.

Yahoo | February 24, 2022

NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome

WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). The trial will be conducted at the Baylor College of Medicine in collaboration with the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP). The principal investigator is Dr. Bij

Yahoo | February 24, 2022

NeuroMetrix reports Q4 results (NASDAQ:NURO)

NeuroMetrix press release (NURO): Q4 net loss of $1MRevenue of $1.82M (+0.6% Y/Y).

Seeking Alpha | January 27, 2022

NeuroMetrix, Inc.''s (NURO) CEO Dr. Shai Gozani on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | January 27, 2022

Read More 'NURO' Stories Here

NURO Price Returns

1-mo 20.42%
3-mo -7.39%
6-mo -46.10%
1-year 37.33%
3-year -37.34%
5-year -88.38%
YTD -20.12%
2021 58.86%
2020 -26.51%
2019 -43.42%
2018 -56.04%
2017 -70.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7971 seconds.